South San Francisco
Tel: (650) 294-8583
About Mammoth Biosciences
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.
A short narrated animation of the molecular biology of CRISPR diagnostics (45 seconds).
14 articles with Mammoth Biosciences
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
The collaboration, announced Wednesday, aims to make disposable, hand-held diagnostics that are as accurate as lab tests and as easy to use as home pregnancy kits.
Mammoth Strikes Deal with GSK Consumer Healthcare to Develop COVID-19 Test Using CRISPR-Based Pla...
5/20/2020Weeks after Mammoth Biosciences announced its CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the company has struck a deal with GSK to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
Following news of Mammoth Biosciences’ CRISPR diagnostic assay to detect SARS-CoV-2, the company talked at length with BioSpace about this new test and its ramifications.
The Mammoth DETECTR assay was validated in less than two weeks and can deliver results in less than 45 minutes.
2/6/2020The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagn...
Mammoth Biosciences Raises $45 Million to Build Next Generation CRISPR Products For Therapeutics and Diagnostics
Already the leader in CRISPR-based disease detection, the latest round will drive Mammoth’s robust platform for protein discovery to extend into gene-editing and therapeutics applications.
1/16/2020Companies from across the globe provide updates to their business and pipeline.
Horizon Discovery Group plc (LSE: HZD) ("Horizon" or “the Group”), a global leader in the application of gene editing and gene modulation technologies, has announced that it has signed a collaboration and license agreement with Mammoth Biosciences (“Mammoth” or the “Company”), to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic antibodies.
12/20/2019Pharma, biotech and life sciences organizations strengthen their leadership teams and boards.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces a strategic collaboration with Mammoth Biosciences, that will see the two companies develop new CRISPR tools to provide the next generation of engineered cell lines for the biopharmaceutical industry.
San Francisco-based Mammoth Biosciences, co-founded by one of the originators of CRISPR gene editing, Jennifer Doudna, closed on a $23 million Series A financing round.
Mammoth Biosciences, based in San Francisco, has officially launched to develop CRISPR technology for clinical diagnostics.